磁共振成像对限制型心肌病诊断价值的研究进展

刘慧; 杨志刚; 郭应坤

doi:10.13201/j.issn.1001-1439.2018.12.003

磁共振成像对限制型心肌病诊断价值的研究进展

- 1 四川大学华西第二医院放射科出生缺陷与相关妇儿疾病教育部重点实验室(成都, 610041);
- 2 四川大学华西医院放射科

详细信息

通讯作者: 郭应坤,E-mail:gykpanda@163.com

中图分类号: 542542.2

收稿日期: 2018-07-23

Research advances of diagnostic value of magnetic resonance imaging in restrictive cardiomyopathy

- 1 Department of Radiology, Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, 610041, China;
- 2 Department of Radiology, West China Hospital, Sichuan University

More Information

Corresponding author: GUO Yingkun, E-mail: gykpanda@163.com

Received Date: 23 July 2018

摘要

摘要: 限制型心肌病 (restrictive cardiomyopathy, RCM) 在临床上尚缺乏统一的诊断标准, 传统的检查方法如超声、心血管造影主要通过心脏形态及血流动力学的改变提供一定的诊断依据, 但缺乏心肌组织学改变的诊断依据。心脏磁共振 (cardiac magnetic resonance, CMR) 时间及空间分辨率高, 可实现心脏动态电影、首过灌注、延迟强化、T1 mapping、心肌应力及T2^*等多参数、多序列成像, 提供解剖学、功能学甚至组织学方面的信息, 以其准确性、无创性及多参数成像, 成为心功能评价和心肌病诊断的一站式检查。本文介绍了RCM分类、病因及病理生理改变, 重点综述了近年来新兴CMR技术在RCM的诊断及预后评价中的价值。
- 限制型心肌病 /
- 磁共振成像 /
- 诊断
Abstract: At present, restrictive cardiomyopathy (RCM) still lacks a unified diagnostic standard in clinical practice.Traditional examination methods such as ultrasound and cardiovascular angiography only can provide some basis diagnostic mainly through changes of cardiac morphology and hemodynamics, but lack of diagnosis of the myocardial histological changes.Cardiac magnetic resonance has high time and spatial resolution, dynamic cine, the first perfusion, delayed enhancement, T1 mapping, myocardial stress and T2^* can be achieved.CMR have become a one-stop check of cardiac function evaluation and cardiomyopathy diagnosis.This article focuses on the classification, etiology and pathophysiology of RCM, especially the diagnosis and prognosis values of new CWR techniques for RCM in recent years..
- Restrictive cardiomyopathy /
- magnetic resonance imaging /
- diagnosis

HTML全文

参考文献(42)

[1]	Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies[J].Br Heart J, 1980, 44 (6):672-673.
[2]	Richardson P, McKenna W, Bristow M, et al.Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies[J].Circulation, 1996, 93 (5):841-842.
[3]	Maron BJ, Towbin JA, Thiene G, et al.Contemporary definitions and classification of the cardiomyopathies[J].Circulation, 2006, 113 (14):1807-1816.
[4]	Elliott P, Andersson B, Arbustini E, et al.Classification of the cardiomyopathies:a position statement from the European society of cardiology working group on myocardial and pericardial diseases[J].Eur Heart J, 2008, 29 (2):270-276.
[5]	Zangwill S, Hamilton R.Restrictive cardiomyopathy[J].Pacing Clin Electrophysiol, 2009, 32, Suppl 2:S41-43.
[6]	Ammash NM, Seward JB, Bailey KR, et al.Clinical profile and outcome of idiopathic restrictive cardiomyopathy[J].Circulation, 2000, 101 (21):2490-2496.
[7]	Liu S, Ma C, Ren W, et al.Regional left atrial function differentiation in patients with constrictive pericarditis and restrictive cardiomyopathy:a study using speckle tracking echocardiography[J].Int J Cardiovasc Imaging, 2015, 31 (8):1529-1536.
[8]	曹玉坤, 崔越, 曾文娟, 等.1.5T磁共振定量正常人左室心肌组织特性和心肌应变的初步研究[J].临床心血管病杂志, 2017, 33 (11):1077-1082.
[9]	Vignaux, O.Cardiac sarcoidosis:spectrum of MRI features[J].AJR Am J Roentgenol, 2005, 184 (1):249-254.
[10]	程仙, 张刘燕, 许菲, 等.原发型心肌淀粉样变的治疗进展[J].临床心血管病杂志, 2017, 33 (5):407-410.
[11]	Rammos A, Meladinis V, Vovas G, et al.Restrictive cardiomyopathies:the importance of noninvasive cardiac imaging modalities in diagnosis and treatment-A systematic review[J].Radiol Res Pract, 2017, 15:2874902.
[12]	Syed IS, Glockner JF, Feng D, et al.Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis[J].JACC Cardiovasc Imaging, 2010, 3 (2):155-164.
[13]	Okabe T, Yakushiji T, Hiroe M, et al.Steroid pulse therapy was effective for cardiac sarcoidosis with ventricular tachycardia and systolic dysfunction[J].ESCHeart Fail, 2016, 3 (4):288-292.
[14]	Hulten E, Aslam S, Osborne M, et al.Cardiac sarcoidosis-state of the art review[J].Cardiovasc Diagn T-her, 2016, 6 (1):50-63.
[15]	Smedema JP, Snoep G, van Kroonenburgh MP, et al.Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis[J].J Am Coll Cardiol, 2005, 45 (10):1683-1690.
[16]	Greulich S, Deluigi CC, Gloekler S, et al.CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis[J].J Am Coll Cardiol, 2013, 6 (4):501-511.
[17]	Crawford T, Mueller G, Sarsam S, et al.Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias[J].Circ Arrhythm Electrophysiol, 2014, 7 (6):1109-1115.
[18]	Ise T, Hasegawa T, Morita Y, et al.Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis[J].Heart, 2014, 100 (15):1165-1172.
[19]	Maia CP, Gali LG, Schmidt A, et al.A challenging differential diagnosis:distinguishing between endomyocardial fibrosis and apical hypertrophic cardiomyopathy[J].Echocardiography, 2016, 33 (7):1080-1084.
[20]	Dato I.How to recognize endomyocardial fibrosis?[J].J Cardiovasc Med, 2015, 16 (8):547-551.
[21]	Moon JC, Sachdev B, Elkington AG, et al.Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease.Evidence for a disease specific abnormality of the myocardial interstitium[J].Eur Heart J, 2003, 24 (23):2151-2155.
[22]	Ogbogu PU, Rosing DR, Horne MK.Cardiovascular manifestations of hypereosinophilic syndromes[J].Immunol Allergy Clin North Am, 2007, 27 (3):457-475.
[23]	Maredia N, English K, Greenwood J.Assessment of endocardial fibroelastosis by cardiac MRI[J].Can JCardiol, 2008, 24 (5):e33.
[24]	Mavrogeni SI, Markussis V, Kaklamanis L, et al.Acomparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major[J].J Haematol, 2005, 75 (3):241-247.
[25]	Tanner MA, Galanello R, Dessi C, et al.A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance[J].Circulation, 2007, 115 (14):1876-1884.
[26]	Saremi F, Grizzard JD, Kim RJ.Optimizing cardiac MRimaging:practical remedies for artifacts[J].Radiographics, 2008, 28 (4):1161-1187.
[27]	Perugini E, Rapezzi C, Reggiani LB, et al.Comparison of ventricular long-axis function in patients with cardiac amyloidosis versus idiopathic restrictive cardiomyopathy[J].Am J Cardiol, 2005, 95 (1):146-149.
[28]	Daniel LR, Kuetting RH, Alois M, et al.Quantitative assessment of systolic and diastolic function in patients with LGE negative systemic amyloidosis using CMR[J].Int J Cardiol, 2017, 232:336-341.
[29]	Pandey T, Alapati S, Wadhwa V, et al.Evaluation of myocardial strain in patients with amyloidosis using cardiac magnetic resonance feature tracking[J].Curr Probl Diagn Radiol, 2017, 46 (4):288-294.
[30]	Williams LK, Forero JF, Popovic ZB, et al.Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics[J].J Cardiovasc Magn Reson, 2017, 19 (1):61-61.
[31]	马敏, 祝烨, 贺勇.心脏磁共振灌注成像在冠状动脉血管病变中的应用进展[J].临床心血管病杂志, 2017, 33 (3):203-206.
[32]	Celletti F, Fattori R, Napoli G, et al.Assessment of restrictive cardiomyopathy of amyloid or idiopathic etiology by magnetic resonance imaging[J].Am J Cardiol, 1999, 83 (5):798-801.
[33]	Miani D, Rocco M, Alberti E, et al.Amyloidosis of epicardial and intramural coronary arteries as an unusual cause of myocardial infarction and refractory angina pectoris[J].Ital Heart J, 2002, 3 (8):479-482.
[34]	Haaf P, Garg P, Messroghli DR, et al.Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice:a comprehensive review[J].J Cardiovasc Magn Reson, 2016, 18 (1):89-89.
[35]	Messroghli DR, Moon JC, Ferreira VM, et al.Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume:A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)[J].J Cardiovasc Magn Reson, 2017, 19 (1):75-75.
[36]	Karamitsos TD, Piechnik SK, Banypersad SM, et al.Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis[J].J Am Coll Cardiol, 2013, 6 (4):488-497.
[37]	Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al.Magnetic resonance in transthyretin cardiac amyloidosis[J].J Am Coll Cardiol, 2017, 70 (4):466-477.
[38]	Pica S, Sado DM, Maestrini V, et al.Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance[J].J Cardiovasc Magn Reson, 2014, 16 (1):99-99.
[39]	Breen JF.Imaging of the pericardium[J].J Thorac Imaging, 2001, 16 (1):47-54.
[40]	Sechtem U, Tscholakoff D, Higgins CB.MRI of the abnormal pericardium[J].Am J Roentgenol, 1986, 47 (2):245-252.
[41]	Masui T, Finck S, Higgins CB.Constrictive pericarditis and restrictive cardiomyopathy:evaluation with MRimaging[J].Radiology, 1992, 182 (3):369-373.
[42]	Matsouka H, Hamada M, Honda T, et al.Evaluation of acute myocarditis and pericarditis by Gd-DTPA enhanced magnetic resonance imaging[J].Eur Heart J, 1994, 15 (2):283-289.